NVS Jan 2026 150.000 call
OPR - OPR Delayed Price. Currency in USD
Add to watchlist
As of 10:36AM EDT. Market open.
| Previous Close | 0.8000 |
| Open | 0.8000 |
| Bid | 0.1500 |
| Ask | 4.9000 |
| Strike | 150.00 |
| Expire Date | 2026-01-16 |
| Day's Range | 0.8000 - 0.8000 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 6 |
- Thomson Reuters StreetEvents
Q1 2024 Legend Biotech Corp Earnings Call
Q1 2024 Legend Biotech Corp Earnings Call
GlobeNewswireArvinas Reports First Quarter 2024 Financial Results and Provides Corporate Update
– Continued enrollment globally in multiple clinical studies of vepdegestrant in ER+/HER2- metastatic breast cancer, including the VERITAC-2 Phase 3 trial in the second-line setting and the study lead-in for the VERITAC-3 Phase 3 trial in the first-line setting – – Top-line data readout for VERITAC-2 remains on-track for 2H 2024 – – Entered a transaction with Novartis providing an exclusive license for ARV-766 and sale of preclinical AR-V7 program; $150 million upfront payment and potential for
The TelegraphQuestor: this medical stock is expensive – but worth paying for
It’s a stock market rule of thumb that big acquisitions tend to destroy shareholder value. Spin-offs, on the other hand, have the reassuring habit of being more likely to create it.
© 2024 Yahoo. All rights reserved.